Philippe Couratier

List of Publications by Year
in descending order

85	4,369	136885	114418
papers	citations	32 h-index	63 g-index

94	94	94	5031
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Reply to the letter from Gazulla. European Journal of Neurology, 2022, 29, e3-e4.	1.7	0
2	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Science Translational Medicine, 2022, 14, eabj0264.	5.8	38
3	Hypermetabolism is a reality in amyotrophic lateral sclerosis compared to healthy subjects. Journal of the Neurological Sciences, 2021, 420, 117257.	0.3	23
4	Genetic screening of ANXA11 revealed novel mutations linked to amyotrophic lateral sclerosis. Neurobiology of Aging, 2021, 99, 102.e11-102.e20.	1.5	20
5	The Effect of <scp>SMN</scp> Gene Dosage on <scp>ALS</scp> Risk and Disease Severity. Annals of Neurology, 2021, 89, 686-697.	2.8	10
6	Time-trend evolution and determinants of sex ratio in Amyotrophic Lateral Sclerosis: a doseâ€“response meta-analysis. Journal of Neurology, 2021, 268, 2973-2984.	1.8	13
7	Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSAâ€FLUO Trial. Movement Disorders, 2021, 36, 1704-1711.	2.2	18
8	Comparison of the ability of the Kingâ€™s and MiToS staging systems to predict disease progression and survival in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 1-9.	1.1	6
9	Familial clustering of primary lateral sclerosis and amyotrophic lateral sclerosis: Supplementary evidence for a continuum. European Journal of Neurology, 2021, 28, 2780-2783.	1.7	9
10	Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 821-831.	4.9	9
11	Primary progressive aphasias associated with C9orf72 expansions: Another side of the story. Cortex, 2021, 145, 145-159.	1.1	9
12	SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. Brain, 2021, 144, 2798-2811.	3.7	7
13	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	9.4	223
14	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	4.9	175
15	Increased resting energy expenditure compared with predictive theoretical equations in amyotrophic lateral sclerosis. Nutrition, 2020, 77, 110805.	1.1	9
16	Predictive factors for gastrostomy at time of diagnosis and impact on survival in patients with amyotrophic lateral sclerosis. Clinical Nutrition, 2020, 39, 3112-3118.	2.3	14
17	Validity of death certificates in the identification of cases of amyotrophic lateral sclerosis (ALS) in the Limousin region, France. A population-based study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 228-234.	1.1	5
18	Vitamin D status among patients with drug-resistant and non-drug-resistant epilepsy. International Journal for Vitamin and Nutrition Research, 2020, 90, 205-209.	0.6	3

#	Article	IF	Citations
19	ATXN1 repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization. Brain Communications, 2020, 2, fcaa064.	1.5	33
20	Metabo-lipidomics of Fibroblasts and Mitochondrial-Endoplasmic Reticulum Extracts from ALS Patients Shows Alterations in Purine, Pyrimidine, Energetic, and Phospholipid Metabolisms. Molecular Neurobiology, 2019, 56, 5780-5791.	1.9	34
21	Residential exposure to ultra high frequency electromagnetic fields emitted by Global System for Mobile (GSM) antennas and amyotrophic lateral sclerosis incidence: A geo-epidemiological population-based study. Environmental Research, 2019, 176, 108525.	3.7	9
22	Amyotrophic lateral sclerosis mortality rates among ethnic groups in a predominant admixed population in Latin America: a population-based study in Ecuador. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 404-412.	1.1	4
23	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism and Related Disorders, 2019, 60, 138-145.	1.1	7
24	Resting energy expenditure equations in amyotrophic lateral sclerosis, creation of an ALS-specific equation. Clinical Nutrition, 2019, 38, 1657-1665.	2.3	13
25	Nutrition parentÃ©rale et sclÃ©rose latÃ©rale amyotrophique (SLA). Nutrition Clinique Et Metabolisme, 2019, 33, 139-144.	0.2	0
26	Phenotypic and genotypic studies of ALS cases in ALS-SMA families. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 432-437.	1.1	8
27	Age-specific ALS incidence: a doseâ€“response meta-analysis. European Journal of Epidemiology, 2018, 33, 621-634.	2.5	46
28	Predictors of Rapid Cognitive Decline in Patients with Mild-to-Moderate Alzheimer Disease: A Prospective Cohort Study with 12-Month Follow-Up Performed in Memory Clinics. Dementia and Geriatric Cognitive Disorders, 2018, 45, 56-65.	0.7	29
29	Early Cognitive, Structural, and Microstructural Changes in Presymptomatic C9orf72 Carriers Younger Than 40 Years. JAMA Neurology, 2018, 75, 236.	4.5	108
30	Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurology, The, 2018, 17, 423-433.	4.9	342
31	Liver X Receptor Genes Variants Modulate ALS Phenotype. Molecular Neurobiology, 2018, 55, 1959-1965.	1.9	28
32	History and current difficulties in classifying inherited myopathies and muscular dystrophies. Journal of the Neurological Sciences, 2018, 384, 50-54.	0.3	14
33	Structural, Microstructural, and Metabolic Alterations in Primary Progressive Aphasia Variants. Frontiers in Neurology, 2018, 9, 766.	1.1	33
34	Referral bias in ALS epidemiological studies. PLoS ONE, 2018, 13, e0195821.	1.1	22
35	Some new proposals for the classification of inherited myopathies. Journal of the Neurological Sciences, 2018, 391, 118-119.	0.3	2
36	Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. International Journal of Epidemiology, 2017, 46, dyw061.	0.9	202

#	Article	IF	Citations
37	A novel mutation of the C-terminal amino acid of FUS (Y526C) strengthens FUS gene as the most frequent genetic factor in aggressive juvenile ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 298-301.	1.1	21
38	Validity of medico-administrative data related to amyotrophic lateral sclerosis in France: A population-based study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 24-31.	1.1	9
39	July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 471-474.	1.1	41
40	Characteristics and Prognosis of Oldest Old Subjects with Amyotrophic Lateral Sclerosis. Neuroepidemiology, 2017, 49, 64-73.	1.1	13
41	Novel UBQLN2 mutations linked to amyotrophic lateral sclerosis and atypical hereditary spastic paraplegia phenotype through defective HSP70-mediated proteolysis. Neurobiology of Aging, 2017, 58, 239.e11-239.e20.	1.5	50
42	Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment*. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 519-527.	1.1	17
43	Management and therapeutic perspectives in amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics, 2017, 17, 263-276.	1.4	29
44	Current view and perspectives in amyotrophic lateral sclerosis. Neural Regeneration Research, 2017, 12, 181.	1.6	26
45	Population-Based Evidence that Survival in Amyotrophic Lateral Sclerosis Is Related to Weight Loss at Diagnosis. Neurodegenerative Diseases, 2016, 16, 225-234.	0.8	39
46	Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial. Lancet Neurology, The, 2016, 15, 1217-1227.	4.9	65
47	Pure cerebellar ataxia linked to large C9orf72 repeat expansion. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 301-303.	1.1	15
48	Stratification of ALS patientsâ€™ survival: a population-based study. Journal of Neurology, 2016, 263, 100-111.	1.8	27
49	Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin. European Journal of Epidemiology, 2016, 31, 229-245.	2.5	87
50	Searching for a link between the L-BMAA neurotoxin and amyotrophic lateral sclerosis: a study protocol of the French BMAALS programme. BMJ Open, 2014, 4, e005528-e005528.	0.8	25
51	Epidemiological evidence that physical activity is not a risk factor for ALS. European Journal of Epidemiology, 2014, 29, 459-475.	2.5	44
52	C9ORF72 Repeat Expansions in the Frontotemporal Dementias Spectrum of Diseases: A Flow-chart for Genetic Testing. Journal of Alzheimer's Disease, 2013, 34, 485-499.	1.2	93
53	Describing perceived stigma against Alzheimer's disease in a general population in France: the STIGâ€MA survey. International Journal of Geriatric Psychiatry, 2013, 28, 933-938.	1.3	40
54	Juvenile and adult-onset ALS/MND among Africans: incidence, phenotype, survival: A review. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 276-283.	2.3	29

#	Article	IF	Citations
55	Early onset Parkinsonism associated with an intronic SOD1 mutation. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 315-317.	2.3	3
56	First assessment at home of amyotrophic lateral sclerosis (ALS) patients by a nutrition network in the French region of Limousin. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 538-543.	2.3	8
57	Contribution of geolocalisation to neuroepidemiological studies: Incidence of ALS and environmental factors in Limousin, France. Journal of the Neurological Sciences, 2011, 309, 115-122.	0.3	29
58	Troubles nutritionnels lors de la sclÃ©rose latÃ©rale amyotrophique (SLA). Nutrition Clinique Et Metabolisme, 2011, 25, 205-216.	0.2	2
59	The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 1-10.	2.3	107
60	Memantine in Behavioral Variant Frontotemporal Dementia: Negative Results. Journal of Alzheimer's Disease, 2011, 23, 749-759.	1.2	107
61	Development and validation of an instrument to detect depression in nursing homes. Nursing homes short depression inventory (NHâ€SDI). International Journal of Geriatric Psychiatry, 2011, 26, 853-859.	1.3	9
62	Can Mortality Data Be Used to Estimate Amyotrophic Lateral Sclerosis Incidence?. Neuroepidemiology, 2011, 36, 29-38.	1.1	61
63	Specific psychological and behavioral symptoms of depression in patients with dementia. International Journal of Geriatric Psychiatry, 2010, 25, 1065-1072.	1.3	49
64	SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. Journal of Medical Genetics, 2010, 47, 554-560.	1.5	266
65	High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 113-117.	2.3	135
66	TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Annals of Neurology, 2009, 65, 470-473.	2.8	278
67	A Mutation that Creates a Pseudoexon in SOD1 Causes Familial ALS. Annals of Human Genetics, 2009, 73, 652-657.	0.3	32
68	Incidence of amyotrophic lateral sclerosis in the Limousin region of France, 1997â€“2007. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 216-220.	2.3	39
69	Prognosis of ALS: Comparing data from the Limousin referral centre, France, and a Uruguayan population. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 355-360.	2.3	17
70	Phase angle is a prognostic factor for survival in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 273-278.	2.3	60
71	Disease progression and survival in ALS: First multiâ€state model approach. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 224-229.	2.3	20
72	What can we do for ALS patients with low vital capacity needing a digestive access for enteral nutrition?. Clinical Nutrition, 2006, 25, 705.	2.3	1

#	Article	IF	Citations
73	Complications and survival following radiologically and endoscopically-guided gastrostomy in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 88-93.	2.3	49
74	Fatigue as the main presenting symptom of chronic inflammatory demyelinating polyradiculoneuropathy: a study of 11 cases. Journal of the Peripheral Nervous System, 2005, 10, 329-337.	1.4	32
75	Hypermetabolism in ALS: Correlations with Clinical and Paraclinical Parameters. Neurodegenerative Diseases, 2005, 2, 202-207.	0.8	208
76	Spirometerâ€dependence of vital capacity in ALS: Validation of a portable device in 52 patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 239-245.	2.3	2
77	Stress oxydant et maladies neurodÃ©gÃ©nÃ©ratives. Nutrition Clinique Et Metabolisme, 2002, 16, 253-259.	0.2	25
78	Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. American Journal of Clinical Nutrition, 2001, 74, 328-334.	2.2	304
79	Gastrostomies et maladies neuromusculaires. Nutrition Clinique Et Metabolisme, 2000, 14, 142-148.	0.2	5
80	Estimation of the amyotrophic lateral sclerosis incidence by capture-recapture method in the Limousin region of France. Journal of Clinical Epidemiology, 2000, 53, 1025-1029.	2.4	45
81	Serum autoantibodies to neurofilament proteins in sporadic amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 1998, 154, 137-145.	0.3	50
82	Ultrastructural PMP22 expression in inherited demyelinating neuropathies. Annals of Neurology, 1996, 39, 813-817.	2.8	136
83	ABNORMAL PHOSPHORYLATION OF TAU PROTEIN IN PRIMARY NEURONAL CULTURES: A CONFOCAL MICROSCOPY STUDY. Biology of the Cell, 1993, 79, 279-279.	0.7	0
84	Tau antigenic changes induced by glutamate in rat primary culture model: A biochemical approach. Neuroscience Letters, 1992, 140, 206-210.	1.0	33
85	A dose-dependent increase of Tau immunostaining is produced by glutamate toxicity in primary neuronal cultures. Brain Research, 1992, 572, 242-246.	1.1	46